About 10 companies from Indonesia, South Korea, Singapore and other countries have filed to list on the Hong Kong Exchange (HKEX) in 2026 [1, 2]. These foreign IPO hopefuls operate in sectors including technology, consumer goods, and financial services [1, 2].
The filings include various listing types such as first-time IPOs, concurrent dual listings, and sequential dual listings, reflecting diverse capital-raising strategies [1, 2]. HKEX is actively broadening its appeal to international firms without direct business exposure to Greater China, shifting from its traditional focus on the region [1, 2].
Johnson Chui, head of global issuer services at HKEX, said, "We feel that this is the start of a structural change of the next phase of international companies listing in Hong Kong. The nexus is broadening. In the past it was more: do you have business exposure in Greater China? But now, there are very successful examples for companies that have no business at all in this part of the world" [2].
HKEX was the world’s top market for IPOs in 2025, raising US$37.4 billion from 115 deals, mostly by Chinese and Hong Kong firms [1, 2]. Among them, 110 Chinese and Hong Kong companies raised US$36.4 billion on the exchange last year alone [1, 2].
In addition to Asian firms, Swiss-based Syngenta Group plans a Hong Kong listing worth up to US$10 billion in the second half of 2026 [1, 2]. Biotech companies Engine Biosciences from Singapore and NiKang Therapeutics from the US are also exploring possible listings on the exchange [2].
The trend suggests HKEX’s continuing efforts to diversify its issuer base and attract a broader set of international companies this year and beyond.
